AIM: To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the post-partum period. METHODS: IMPAACT P1026s is an on-going, prospective, non-blinded study of antiretroviral pharmacokinetics (PK) in HIV-infected pregnant women with a Thai cohort receiving IDV/r 400/100 mg twice daily during pregnancy through to 6-12 weeks post-partum as part of clinical care. Steady-state PK profiles were performed during the second (optional) and third trimesters and at 6-12 weeks post-partum. PK targets were the estimated 10(th) percentile IDV AUC (12.9 μg ml(-1)h) in non-pregnant historical Thai adults and a trough concentration of 0.1 μg ml(-1), the suggested minimum target. RESULTS: Twenty-six pregnant women were enrolled; thirteen entered during the second trimester. Median (range) age was 29.8 (18.9-40.8) years and weight 60.5 (50.0-85.0) kg at the third trimester PK visit. The 90% confidence limits for the geometric mean ratio of the indinavir AUC(0,12 h) and Cmax during the second trimester and post-partum (ante : post ratios) were 0.58 (0.49, 0.68) and 0.73 (0.59, 0.91), respectively; third trimester/post-partum AUC(0,12 h) and Cmax ratios were 0.60 (0.53, 0.68) and 0.63 (0.55, 0.72), respectively. IDV/r was well tolerated and 21/26 women had a HIV-1 viral load < 40 copies ml(-1) at delivery. All 26 infants were confirmed HIV negative. CONCLUSION: Indinavir exposure during the second and third trimesters was significantly reduced compared with post-partum and ∼30% of women failed to achieve a target trough concentration. Increasing the dose of IDV/r during pregnancy to 600/100 mg twice daily may be preferable to ensure adequate drug concentrations.
AIM: To describe the pharmacokinetics and safety of indinavir boosted with ritonavir (IDV/r) during the second and third trimesters of pregnancy and in the post-partum period. METHODS: IMPAACT P1026s is an on-going, prospective, non-blinded study of antiretroviral pharmacokinetics (PK) in HIV-infected pregnant women with a Thai cohort receiving IDV/r 400/100 mg twice daily during pregnancy through to 6-12 weeks post-partum as part of clinical care. Steady-state PK profiles were performed during the second (optional) and third trimesters and at 6-12 weeks post-partum. PK targets were the estimated 10(th) percentile IDV AUC (12.9 μg ml(-1)h) in non-pregnant historical Thai adults and a trough concentration of 0.1 μg ml(-1), the suggested minimum target. RESULTS: Twenty-six pregnant women were enrolled; thirteen entered during the second trimester. Median (range) age was 29.8 (18.9-40.8) years and weight 60.5 (50.0-85.0) kg at the third trimester PK visit. The 90% confidence limits for the geometric mean ratio of the indinavir AUC(0,12 h) and Cmax during the second trimester and post-partum (ante : post ratios) were 0.58 (0.49, 0.68) and 0.73 (0.59, 0.91), respectively; third trimester/post-partum AUC(0,12 h) and Cmax ratios were 0.60 (0.53, 0.68) and 0.63 (0.55, 0.72), respectively. IDV/r was well tolerated and 21/26 women had a HIV-1 viral load < 40 copies ml(-1) at delivery. All 26 infants were confirmed HIV negative. CONCLUSION:Indinavir exposure during the second and third trimesters was significantly reduced compared with post-partum and ∼30% of women failed to achieve a target trough concentration. Increasing the dose of IDV/r during pregnancy to 600/100 mg twice daily may be preferable to ensure adequate drug concentrations.
Authors: Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse Journal: Antimicrob Agents Chemother Date: 2004-03 Impact factor: 5.191
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl Journal: N Engl J Med Date: 1997-09-11 Impact factor: 91.245
Authors: Jashvant D Unadkat; Diane W Wara; Michael D Hughes; Anita A Mathias; Diane T Holland; Mary E Paul; James Connor; Sharon Huang; Bach-Yen Nguyen; D Heather Watts; Lynne M Mofenson; Elizabeth Smith; Paul Deutsch; Kathleen A Kaiser; Ruth E Tuomala Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: A Hsu; G R Granneman; G Cao; L Carothers; A Japour; T El-Shourbagy; S Dennis; J Berg; K Erdman; J M Leonard; E Sun Journal: Antimicrob Agents Chemother Date: 1998-11 Impact factor: 5.191
Authors: Anna H Tran; Brookie M Best; Alice Stek; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Kathleen George; Tim R Cressey; Nahida Chakhtoura; Elizabeth Smith; David E Shapiro; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Alice Stek; Brookie M Best; Jiajia Wang; Edmund V Capparelli; Sandra K Burchett; Regis Kreitchmann; Kittipong Rungruengthanakit; Tim R Cressey; Lynne M Mofenson; Elizabeth Smith; David Shapiro; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731